A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects

British Journal of Clinical Pharmacology

Volumn 75, Issue 6, 2013, Pages 1396-1405

  Turtle, Emma J ^a   Dear, James W ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acetaminophen; Blood pressure; Hypertension; Paracetamol; Prostaglandins; Review

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPHENIRAMINE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; IBUPROFEN; METHYLDOPA; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO; PSEUDOEPHEDRINE; VASODILATOR AGENT;

ARTICLE; BLOOD PRESSURE; COCHRANE LIBRARY; EMBASE; HUMAN; HYPERTENSION; MEDLINE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84878150576     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12032     Document Type: Article

References (78)

1. Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM. Paracetamol toxicity: epidemiology, prevention and costs to the health-care system. Q J Med 2002; 95: 609-619.
2. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006; 79: 9-19.
3. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008; 70: 357-377.
4. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005; 112: 759-770.
5. Mburu DN, Mbugua SW, Skoglund L, Lokken L. Effects of paracetamol and acetylsalicylic acid on the post-operative course after experimental orthopaedic surgery in dogs. J Vet Pharmacol Ther 1998; 11: 163-171.
6. Lokken P, Skjelbred P. Analgesic and anti-inflammatory effect of paracetamol evaluated by bilateral oral surgery. Br J Clin Pharmacol 1980; 10: 253S-260.
7. Seymour RA, Williams FM, Oxley A, Ward A, Fearns M, Brighan K, Rawlins MD, Jones PM. A comparative study of the effects of aspirin and paracetamol (acetaminophen) on platelet aggregation and bleeding time. Eur J Clin Pharmacol 1984; 26: 567-571.
8. Feldberg W, Gupta K, Milton A, Wendland S. Effect of pyrogen and antipyretics on prostaglandin activity in cisternal CSF of anaesthetised cats. J Physiol 1973; 234: 279-303.
9. Ferarri RA, Ward SJ, Zobre CM, Van Liew DK, Perrone MH, Connell MJ, Haubrich DR. Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur J Pharmacol 1990; 179: 25-34.
10. Chandrasekharan NV, Dai H, Lamar Turepu Roos K, Evanson NK, Tomsik J, Elton TS. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926-13931.
11. Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995; 103: 1-44.
12. Hunskaar S, Fasmer OB, Hole K. Acetylsalicylic acid, paracetamol and morphine inhibit behavioral responses to intrathecally administered substance P or capsaicin. Life Sci 1985; 37: 1835-1841.
13. Pickering G, Esteve V, Loriot MA, Eschalier A, Dubray C. Acetaminophen reinforces descending inhibitory pain pathways. Clin Pharmacol Ther 2008; 84: 47-51.
14. Hogestatt ED, Jonsson BA, Ermund A, Anderson DA, Bjork H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005; 280: 31405-31412.
15. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 2006; 531: 280-281.
16. Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Högestätt ED, Zygmunt PM. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol. Nat Commun 2011; 22: 551.
17. Graham G, Scott K. Mechanisms of action of paracetamol. Am J Ther 2005; 12: 46-55.
18. Bijlsma JW, Berenbaum F, Lafeber F. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377: 2115-2126.
19. Pope J, Anderson J, Felson D. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-484.
20. Johnston A, Nguyen M, Day R. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.
21. Aw T, Haas S, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-496.
22. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226-2235.
23. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network analysis. BMJ 2011; 342: c7086.
24. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901-907.
25. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010; 44: 489-506.
26. NICE clinical guideline 59; The care and management of osteoarthritis in adults. February 2008. Available at http://www.nice.org.uk/guidance/CG59 (last accessed 29 October 2012).
27. Antman EM, Bennet JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs. An update for clinicians. Circulation 2007; 115: 1634-1642.
28. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile S, Corti R, Vanhoutte PM, Luscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010; 122: 1789-1796.
29. Montori VM, Wilczynski NL, Morgan D, Haynes RB. Optimal search strategies for retrieving systematic reviews from Medline: analytical survey. BMJ 2005; 330: 68.
30. Douglas L, Akil M. Sodium in soluble paracetamol may be linked to raised blood pressure. BMJ 2006; 332: 1133.
31. Montgomery B. Does paracetamol cause hypertension? BMJ 2008; 336: 1190-1191.
32. Gaillard M, Mathiaux F, Aldigier J, Laroche M, Nouaille Y, Merle L. Paracetamol use and risk of hypertension: Case report and literature review. Fundamental and Clinical Pharmacology. Conference Publication. 2011.
33. Ubeda A, Llopico J, Sanchez MT. Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. Pharmacoepidemiol Drug Saf 2009; 18: 417-419.
34. Boyle M, Hundy S, Torda TA. Paracetamol administration is associated with hypotension in the critically ill. Aust Crit Care 1997; 10: 120-122.
35. Dedier J, Stampfer MJ, Hankinson SE, Willet WC, Speizer FE, Curham GC. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40: 604-608.
36. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002; 162: 2204-2208.
37. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005; 46: 500-507.
38. Kurth T, Hennekens CH, Stürmer TH, Sesso HD, Glynn RJ, Buring JE, Gaziano M. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med 2005; 165: 1903-1909.
39. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167: 394-399.
40. Chalmers JP, West MJ, Wing LMH, Bune AJC, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clin Exp Hypertens 1984; 6: 1077-1093.
41. Lewis RV, Toner JM, Jackson PR, Ramsay LE. Effects of indomethacin and sulindac on blood pressure of hypertensive patients. BMJ 1986; 292: 934-935.
42. Radack K, Deck C, Bloomfield S. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 1987; 107: 628-635.
43. Chua SS, Benrimoj SI, Gordon RD, Williams G. Cardiovascular effects of a chlorpheniramine/paracetamol combination in hypertensive patients who were sensitive to the pressor effect of pseudoephedrine. Br J Clin Pharmacol 1991; 31: 360-362.
44. Pavličević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008; 15: 372-382.
45. Brotman DJ. Acetaminophen and hypertension: a causal association or pain mediated? Arch Intern Med 2003; 163: 1115-1116.
46. Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006; 24: 1457-1469.
47. Sudano I, Flammer AJ, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep 2012; 14: 304-309.
48. Friedrich I, Bonatz A, Schwenke K. Sodium content of effervescent analgesics. February 2011. Available at http://www.industrialpharmacy.eipg.eu (last accessed 21 September 2012).
49. NICE clinical guideline 127; Clinical management of hypertension in adults. August 2011. Available at http://www.nice.org.uk/guidance/CG127 (last accessed 29 October 2012).
50. Tronvik E, Stovner LJ, Hagan K, Holmen J, Zwart JA. High pulse pressure protects against headache: prospective and cross sectional data (HUNT Study). Neurology 2008; 70: 1329-1336.
51. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H. Low-dose aspirin does not interfere with the blood pressure lowering effects of antihypertensive therapy. J Hypertens 2002; 20: 1015-1022.
52. Zamir N, Maixner W. The relationship between cardiovascular and pain regulatory systems. Ann N Y Acad Sci 1986; 467: 371-384.
53. Chua SS, Benrimoj SI, Gordon RD, Williams G. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients. Br J Clin Pharmacol 1989; 28: 369-372.
54. Britton MG, Empey DW, John GC, McDonnell KA, Hughes DT. Histamine challenge and anterior nasal rhinometry: their use in the assessment of pseudoephedrine and triprolidine as nasal decongestants in subjects with hayfever. Br J Clin Pharmacol 1978; 6: 51-58.
55. Empey DW, Frosolono MF, Hughes DT, Perkins JG. Comparison of pseudoephedrine and triprolidine, alone and in combination in preventing nasal congestion in subjects with allergic rhinitis using nasal histamine challenge. Br J Clin Pharmacol 1984; 18: 86-89.
56. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled in amlodipine or enalapril. Am J Hypertens 2000; 13: 1161-1167.
57. Houston MC, Weir M, Gray J, Ginsberg D, Szeto C, Kaihlenen PM, Sugimoto D, Runde M, Lefkowitz M. The effect of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155: 1049-1054.
58. Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Physiol 1977; 233: 169-184.
59. Gerber JG, Olson RD, Nies AS. Interrelationship between prostaglandins and renin release. Kidney Int 1981; 19: 816-821.
60. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis S. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465-1470.
61. McAdam BF, Catella-Lawson F, Mardini SK, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96: 272-277.
62. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald G. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-741.
63. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater C, Yao SL. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet. Ann Intern Med 2000; 133: 1-9.
64. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84.
65. Patrono C, Wennmalm A, Ciabattoni G, Nowak J, Pugliese F, Cinotti GA. Evidence for extra-renal origin of urinary prostaglandins in healthy men. Prostaglandins 1979; 18: 623-629.
66. Prescott L, Mattison P, Menzies G, Manson LM. The comparative effects of paracetamol and indomethacin on renal function in healthy female volunteers. Br J Clin Pharmacol 1990; 29: 403-412.
67. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A 2012; 109: 17597-17602.
68. Green K, Drvota V, Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen. Prostaglandins 1989; 37: 311-315.
69. Haylor J. Prostaglandin synthesis and renal function in man. J Physiol 1980; 298: 383-396.
70. Bippi H, Frolich JC. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man. Br J Clin Pharmacol 1990; 29: 305-310.
71. Izhar M, Alausa T, Folker A, Hung E, Bakris B. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated Blacks and Hispanics. Hypertension 2004; 43: 573-577.
72. Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C, DeLucca P, Demopoulos L. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000; 36: 461-465.
73. Fogari R, Zoppi A, Carretta C. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 2002; 20: 1007-1014.
74. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. A randomized controlled trial. JAMA 2006; 296: 87-93.
75. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007; 26: 283-290.
76. Heard KJ, Green JL, Dart RC. Serum alanine aminotransferase elevation during 10 days of acetaminophen administration in non-drinkers. Pharmacotherapy 2010; 30: 818-822.
77. Doherty M, Hawkey C, Goulder M, Gibb I, Hill N, Aspley S, Reader S. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community derived people with knee pain. Ann Rheum Dis 2011; 70: 1534-1541.
78. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.